Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00802906

Enrollment

Registered

2008-12-05

Start date

2007-05-31

Completion date

2010-12-31

Last updated

2012-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Keywords

micropulselaserphotocoagulation, bevacizumab, CSC

Brief summary

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Detailed description

To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.

Interventions

DEVICEsubthreshold micropulselaser

on demand if leakage is persistent or recurs after initial treatment

DRUGbevacizumab

1.5 mg initial intravitreal injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* CSC of \>4 months duration

Exclusion criteria

* History of macular or chorioretinal inflammation * Lens / corneal opacities

Design outcomes

Primary

Measure	Time frame
BCVA in EDTRS values	24 months

Secondary

Measure	Time frame
OCT, leakage in FA, defects in satic perimetry	24 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026